Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc.

AMPH

$24.96

Updated: 24/09/2026, 08:05:18

Market Cap
$1.10B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Stock valuation chart
One-year closing share-price history for AMPH
Company Profile

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

USD
NASDAQ
CEO: Yongfeng Zhang
Employees: 1,976
https://www.amphastar.com
Asset Summaries
Latest generated summaries for AMPH

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for AMPH.
Share price
$24.96
Market cap
$1.10B
Exchange
NASDAQ
Currency
USD
CEO
Yongfeng Zhang
Employees
1,976
IPO date
25/06/2014
Beta
0.915
Last dividend
$0.00
Day range
$24.30 – $25.12
52-week range
$16.65 – $29.52
1-day performance
2.63%
1-year performance
49.91%
Current drawdown (1Y)
-15.45%
CIK
0001297184
CUSIP
03209R103
ISIN
US03209R1032
Created
07/12/2025, 02:04:28
Last update
24/09/2026, 08:05:18

Track Amphastar Pharmaceuticals, Inc. with an AI analyst

See which prediction-market events move AMPH, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to AMPH from your Railway `news_articles` table.

Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth

MarketBeat • STOCK • 10/06/2026, 21:09:32

Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

GlobeNewsWire • STOCK • 08/06/2026, 10:19:00

Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag

MarketBeat • STOCK • 04/06/2026, 02:02:26

Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference

Accesswire • STOCK • 27/05/2026, 08:00:00

Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook

MarketBeat • STOCK • 14/05/2026, 04:06:01

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 22:50:46

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 08/05/2026, 08:41:16

Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics

Zacks Investment Research • STOCK • 07/05/2026, 23:01:10

Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates

Zacks Investment Research • STOCK • 07/05/2026, 20:55:25

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026

Accesswire • STOCK • 30/04/2026, 08:00:00

AMPH vs. RDY: Which Stock Should Value Investors Buy Now?

Zacks Investment Research • STOCK • 29/04/2026, 14:41:18

Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?

Zacks Investment Research • STOCK • 29/04/2026, 12:42:39